Patents by Inventor Cheryl Dean

Cheryl Dean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intradermal delivery of vaccines and gene therapeutic agents via microcannula
    Patent number: 7473247
    Abstract: The present invention relates to methods and devices for administration of vaccines and gene therapeutic agents into the intradermal layer of skin.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: January 6, 2009
    Assignee: Becton, Dickinson and Company
    Inventors: John A. Mikszta, Jason B. Alarcon, Cheryl Dean, Andrea Waterston
  • Intradermal cellular delivery using narrow gauge micro-cannula
    Publication number: 20080021439
    Abstract: A method for delivering cells into a subject by administering cells into the intradermal space of the skin of the subject by a microneedle. The cells are associated with cellular based therapeutics and vaccines and delivered by perpendicular insertion of the microneedle. The microneedle is a hollow needle having an exposed height of between about 0 and 1 mm, a total length of between about 0.3 mm to 2.5 mm, and a size of equal to or less than 30 gauge. An array of microneedles can also be used.
    Type: Application
    Filed: February 12, 2007
    Publication date: January 24, 2008
    Applicant: Becton, Dickinson and Company
    Inventors: John Brittingham, John Mikszta, Dominique Williams, Cheryl Dean
  • Intradermal delivery of vacccines and therapeutic agents
    Publication number: 20060018877
    Abstract: The present invention relates to methods and devices for administration of vaccines and therapeutic agents into the intradermal layer of the skin. The methods of the present invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery methods, e.g., intramuscular route. Furthermore, the methods of the present invention facilitate induction of an immune response by an amount of vaccine which is otherwise insufficient for inducing an immune response when delivered via conventional vaccine routes, e.g., intramuscular route.
    Type: Application
    Filed: April 29, 2005
    Publication date: January 26, 2006
    Inventors: John Mikszta, Jason Alarcon, Cheryl Dean, Andrea Hartley
  • Intradermal cellular delivery using narrow gauge micro-cannula
    Publication number: 20050244385
    Abstract: A method for delivering cells into a subject by administering cells into the intradermal space of the skin of the subject by a microneedle. The cells are associated with cellular based therapeutics and vaccines and delivered by perpendicular insertion of the microneedle. The microneedle is a hollow needle having an exposed height of between about 0 and 1 mm, a total length of between about 0.3 mm to 2.5 mm, and a size of equal to or less than 30 gauge. An array of microneedles can also be used.
    Type: Application
    Filed: January 16, 2004
    Publication date: November 3, 2005
    Applicant: Becton Dickinson & Company
    Inventors: John Brittingham, John Mikszta, Dominique Williams, Cheryl Dean
  • Intradermal delivery of vaccines and gene therapeutic agents via microcannula
    Publication number: 20040131641
    Abstract: The present invention relates to methods and devices for administration of vaccines and gene therapeutic agents into the intradermal layer of skin.
    Type: Application
    Filed: October 2, 2003
    Publication date: July 8, 2004
    Inventors: John A. Mikszta, Jason B. Alarcon, Cheryl Dean, Andrea Waterston
  • Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
    Publication number: 20040120964
    Abstract: The present invention relates to a method of vaccinating a subject comprising delivering a chimeric yellow fever 17D strain vector expressing an envelope protein gene product of a heterologous flavivirus to the epidermal compartment or the intradermal compartment of the subject's skin. The invention encompasses vaccine compositions comprising the chimeric yellow fever viruses expressing an envelope protein gene product of a heterologous flavivirus. The compositions of the invention result in an enhanced therapeutic efficacy, e.g., enhanced protective immune response as they enhance the presentation and availability of the chimeric vaccine to the targeted compartment of the subject's skin.
    Type: Application
    Filed: October 2, 2003
    Publication date: June 24, 2004
    Inventors: John A. Mikszta, Jason B. Alarcon, Cheryl Dean, Andrea Waterston, Farshad Guirakhoo, Monath P. Thomas